With the expansion of use, it is estimated that half of the patients who use oral calcitriol would be indicated for paricalcitol because they persist with PTH levels above 300 pg/mL, in the absence of hypercalcemia and hyperphosphatemia, increasing to 20% the use of paricalcitol by patients on dialysis. The gene discussed is PTH; the disease is Hypercalcemia.